IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$7.96 USD
+0.26 (3.38%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $7.95 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
IGMS 7.96 +0.26(3.38%)
Will IGMS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IGMS
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade
Other News for IGMS
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)
IGM Biosciences weakness creates 'interesting opportunity,' says Stifel
What 5 Analyst Ratings Have To Say About IGM Biosciences
IGM Biosciences Announces Refocusing of Sanofi Collaboration